Clinical Efficacy of Ivabradine in Patients With Inappropriate Sinus Tachycardia

Results After taking ivabradine, patients reported elimination of 70% of symptoms (relative risk: 0.25; 95% CI: 0.18 to 0.34; p 0.001), with 47% of them experiencing complete elimination. These effects were associated with a significant reduction of heart rate at rest (from 88 11 beats/min to 76 11 beats/min, p 0.011), on standing (from 108 12 beats/min to 92 11 beats/min, p 0.0001), during 24 h (from 88 5 beats/min to 77 9 beats/min, p 0.001), and during effort (from 176 17 beats/min to 158 16 beats/min, p 0.001). Ivabradine administration was also associated with a significant increase in exercise performance. No cardiovascular side effects were observed in any patients while taking ivabradine.

[1]  F. Fedele,et al.  Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. , 2010, Heart rhythm.

[2]  I. Abidin.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial , 2010 .

[3]  W. Ahmad.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study , 2010 .

[4]  C. Antzelevitch,et al.  The Contribution of HCN4 to Normal Sinus Node Function in Humans and Animal Models , 2010, Pacing and clinical electrophysiology : PACE.

[5]  G. Cayla,et al.  A Case of Cardiomyopathy Induced by Inappropriate Sinus Tachycardia and Cured by Ivabradine , 2009, Pacing and clinical electrophysiology : PACE.

[6]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[7]  W. Shen,et al.  How to manage patients with inappropriate sinus tachycardia. , 2005, Heart rhythm.

[8]  W. Jung,et al.  A Single Intravenous Dose of Ivabradine, a Novel If Inhibitor, Lowers Heart Rate but Does Not Depress Left Ventricular Function in Patients with Left Ventricular Dysfunction , 2003, Cardiology.

[9]  W. Shen,et al.  Modification and ablation for inappropriate sinus tachycardia: current status. , 2002, Cardiac electrophysiology review.

[10]  D. Packer,et al.  Is Sinus Node Modification Appropriate for Inappropriate Sinus Tachycardia with Features of Postural Orthostatic Tachycardia Syndrome? , 2001, Pacing and clinical electrophysiology : PACE.

[11]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[12]  J. Lenfant,et al.  Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells , 1996, British journal of pharmacology.

[13]  C. Morillo,et al.  Inappropriate Sinus Tachycardia: Evaluation and Therapy , 1995, Journal of cardiovascular electrophysiology.

[14]  J. Olgin,et al.  Radiofrequency catheter modification of the sinus node for "inappropriate" sinus tachycardia. , 1995, Circulation.

[15]  K. Rosen,et al.  Chronic nonparoxysmal sinus tachycardia in otherwise healthy persons. , 1979, Annals of internal medicine.

[16]  J. Tardif,et al.  Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. , 2010, The American journal of cardiology.

[17]  C. Lau,et al.  Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S 16257) in Adult Patients with Normal Baseline Electrophysiology , 2003, Drugs in R&D.

[18]  D DiFrancesco,et al.  Pacemaker mechanisms in cardiac tissue. , 1993, Annual review of physiology.